ORIGINAL RESEARCH
The Effect of Combined Use of Intratympanic Steroid Therapy on Sudden Hearing Loss
Ani İşitme Kaybında İntratimpanik Steroid Tedavisinin Kombine Kullanılmasının İşitme Kazancı Üzerine Etkisi
Received Date : 17 Feb 2019
Accepted Date : 29 May 2019
Selda KARGIN KAYTEZa, Mustafa Asım ŞAFAKb, Münir DEMİRCİc
aKulak Burun Boğaz Hastalıkları Kliniği, Sağlık Bilimleri Üniversitesi Ankara Eğitim ve Araştırma Hastanesi,
Ankara, TÜRKİYE
bKulak Burun Boğaz Hastalıkları Kliniği, Memorial Antalya Hastanesi, Antalya, TÜRKİYE
cKulak Burun Boğaz Hastalıkları Kliniği, Yıldırım Beyazıt Üniversitesi Yenimahalle Eğitim ve Araştırma Hastanesi,
Ankara, TÜRKİYE
Doi: 10.24179/kbbbbc.2019-65586 - Makale Dili: TR
KBB ve BBC Dergisi 2019;27(2):51-6
Copyright © 2020 by Turkey Association of Society of Ear Nose Throat and Head Neck Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: The aim of this study was to determine the effects of high-dose systemic
steroid therapy and consecutive intratympanic steroid injections at the beginning of treatment with
lower dose systemic steroid therapy (combined treatment) on the clinical and audiological recovery
in the treatment of sudden hearing loss. Material and Methods: The study was done by retrospective
analysis of the records of 52 patients who were diagnosed with sudden hearing loss between 2002-
2005. Twenty-four of the patients were in the high dose systemic steroid treatment group and 28
were in the intratympanic steroid treatment with lower dose systemic steroid therapy group (combined
treatment). Pure tone averages of 500-1000-2000-4000 Hertz (Hz) frequencies were examined
in the patients before and after treatment. The pure tone averages was determined on these four
thresholds, and differences of 10 dB and above were considered as gain. In the evaluation of the findings;
chi-square test and student-t test were used, p<0.05 was considered statistically significant. Results:
The rate of recovery in pure voice after treatment was 16,7% in the high dose systemic steroid
treatment group and 50% in the combined treatment group. The combined treatment group had
better hearing recovery than in the high dose systemic steroid treatment group. There was no significant
difference in the mean sound gain between the two groups on the 7th, 15th and 30th days. Conclusion:
This study shows that the addition of intratympanic steroid treatment to systemic steroid
therapy increases hearing gain and can reduce the dose of systemic steroids in sudden hearing loss.
Keywords: Drug therapy, combination; hearing loss, sudden; methylprednisolone
ÖZET
Amaç: Ani işitme kaybı tedavisinde, yüksek doz sistemik steroid tedavisinin ve günaşırı ardışık
intratimpanik steroid enjeksiyonunun, başlangıçta daha düşük dozda sistemik steroid tedavisi
(kombine tedavi) ile birlikte verilmesinin klinik ve odyolojik düzelmeye olan etkilerini ortaya çıkarmaktır.
Gereç ve Yöntemler: Bu çalışma; 2002-2005 yılları arasında ani işitme kaybı tanısı konularak
tedavi edilen 52 hastanın dosya kayıtlarının retrospektif olarak incelenmesi ile yapıldı.
Hastaların 24’ü yüksek doz sistemik steroid tedavisi grubunda, 28’i intratimpanik steroid enjeksiyonu
ve düşük dozda sistemik steroid tedavisi grubunda idi (kombine tedavi). Hastaların, tedavi
öncesi ve sonrası odyolojik tetkiklerinde, 500-1000-2000-4000 Hertz (Hz) frekanslarında saf ses ortalamalarına
bakıldı. Saf ses ortalaması bu dört eşikte saptanarak 10 dB ve üzerindeki farklar kazanç
olarak kabul edildi. Bulguların değerlendirilmesinde ki-kare testi ve student-t testi kullanıldı, p<0,05
istatistiksel olarak anlamlı kabul edildi. Bulgular: Tedaviden sonra saf ses ortalamasındaki iyileşme
oranı yüksek doz sistemik steroid tedavi grubunda %16,7, kombine tedavi grubunda %50 idi. Kombine
tedavi grubunda iyileşmedeki düzelme yüksek doz sistemik steroid tedavi grubuna göre daha
iyi bulundu. Her iki tedavi grubunda, yedi, 15 ve 30. günlerde saptanan saf ses ortalama kazançları
karşılaştırıldığında anlamlı fark bulunmadı. Sonuç: Bu çalışma, sistemik steroid tedavi intratimpanik
steroid tedavisinin eklenmesinin, ani işitme kaybında işitme kazancını artırdığını ve sistemik
steroid dozunun azaltılabildiğini göstermektedir.
Anahtar Kelimeler: İlaç tedavisi, kombinasyon; işitme kaybı, ani; metilprednizolon
KAYNAKLAR
- Wilson WR, Veltri RW, Laird N, Sprinkle PM. Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg. 1983;91(6):653-8. [Crossref] [PubMed]
- Chau JK, Lin JR, Atashband S, Irvine RA, Westerberg BD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope. 2010;120(5):1011-21. [Crossref] [PubMed]
- Fetterman BL, Saunders JE, Luxford WM. Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol. 1996;17(4):529-36.
- Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 1984;94(5 Pt 1):664-6. [Crossref]
- Gianoli GJ, Li JC. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg. 2001;125(3):142-6. [Crossref] [PubMed]
- Kopke RD, Hoffer ME, Wester D, O'Leary MJ, Jackson RL. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol. 2001;22(4):475-9. [Crossref] [PubMed]
- Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol. 2001;22(1):18-23. [Crossref] [PubMed]
- Kiliç R, Safak MA, Oğuz H, Kargin S, Demirci M, Samim E, et al. Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol. 2007;28(3):312-6. [Crossref] [PubMed]
- Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2007;117(1):3-15. [Crossref] [PubMed]
- Haberkamp TJ, Tanyeri HM. Management of idiopathic sudden sensorineural hearing loss. Am J Otol. 1999;20(5):587-92.
- Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. Intaratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J. 1996;75(8):468-71. [Crossref] [PubMed]
- Rarey KE, Luttge WG. Presence of type 1 and type II/1B receptors for adrenocorticosteroid hormones in the iner ear. Hear Res. 1989;41(2-3):217-21. [Crossref]
- Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolarngol. 1980;106(12):772-6. [Crossref] [PubMed]
- Cole RR, Jahrsdoerfer RA. Sudden hearing loss: an update. Am J Otol. 1988;9(3):211-5.
- Lefebvre PP, Staecker H. Steroid perfusion of the iner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol. 2002;122(7): 698-702. [Crossref]
- Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M, Connely PE, Huang E, et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of faciliating agents. Otolaryngol Head Neck Surg. 2000;122(4):521-8. [Crossref]
- Parnes LS, Sun AH, Freemann DJ. Corticosteroids pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7 Pt 2):1-17. [Crossref] [PubMed]
- Yang GS, Song HT, Keithley EM, Haris JP. Intratympanic immünosuppressives for prevention of immüno-mediated sensorineural hearing loss. Am J Otol. 2000;21(4):499-504.
- Herr BD, Marzo SJ. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2005;132(4):527-31. [Crossref] [PubMed]
- Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J, et al. Intratympanic steroid treatment: a review. Otol Neurotol. 2004;25(6):1034-9. [Crossref] [PubMed]
- Covelli E, Altabaa K, Verillaud B, Camous D, Hautefort C, Barbara M, et al. Intratympanic steroids as a salvage therapy for severe to profound idiopathic sudden sensorineural hearing loss. Acta Otolaryngol. 2018;138(11): 966-71. [Crossref] [PubMed]
- Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone+high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2008;29;(4):453-60. [Crossref] [PubMed]
- Bae SC, Noh HI, Jun BC, Jeon EJ, Seo JH, Park SY, et al. Efficacy of intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss: comparison with systemic steroid therapy and combined therapy. Acta Otolaryngol. 2013;133(5):428-33. [Crossref] [PubMed]
- Park MK, Lee CK, Park KH, Lee JD, LeeCG, Lee BD. Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2011;145(6): 1016-21. [Crossref] [PubMed]
- Kim SH, Jung SY, Kim MG, Byun JY, Park MS, Yeo SG. Comparison of steroid administration methods in patients with idiopathic sudden sensorineural hearing loss: a retrospective observational study. Clin Otolaryngol. 2015;40(3):183-90. [Crossref] [PubMed]
- Hobson CE, Alexander TH, Harris JP. Primary treatment of idiopathic sudden sensorineural hearing loss with intratympanic dexamethasone. Curr Opin Otolaryngol Head Neck Surg. 2016;24(5):407-12. [Crossref] [PubMed]
- Jung da J, Park JH, Jang JH, Lee KY. The efficacy of combination therapy for idiopathic sudden sensorineural hearing loss. Laryngoscope. 2016;126(8):1871-6. [Crossref] [PubMed]